ZDHHC7

Summary

ZDHHC7 (zDHHC palmitoyltransferase 7, HGNC:18459) is a protein-coding gene on chromosome 16q24.1, encoding Palmitoyltransferase ZDHHC7 (Q9NXF8). Golgi-localized palmitoyltransferase that catalyzes the addition of palmitate onto various protein substrates and therefore functions in several unrelated biological processes.

Enables protein-cysteine S-palmitoyltransferase activity. Involved in several processes, including nuclear receptor-mediated steroid hormone signaling pathway; regulation of protein localization; and regulation of signal transduction. Located in Golgi apparatus and nucleoplasm.

Source: NCBI Gene 55625 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 47 total
• Druggable target: yes
• MANE Select transcript: NM_017740

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18459
Approved symbol	ZDHHC7
Name	zDHHC palmitoyltransferase 7
Location	16q24.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10792, ZNF370, FLJ20279, SERZ-B, SERZ1, DHHC7
Ensembl gene	ENSG00000153786
Ensembl biotype	protein_coding
OMIM	614604
Entrez	55625

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 18 protein_coding, 2 retained_intron, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000313732, ENST00000344861, ENST00000564466, ENST00000564526, ENST00000566909, ENST00000569017, ENST00000569377, ENST00000569488, ENST00000905028, ENST00000905029, ENST00000905030, ENST00000905031, ENST00000905032, ENST00000905033, ENST00000911294, ENST00000911295, ENST00000954815, ENST00000954816, ENST00000954817, ENST00000954818, ENST00000954819, ENST00000954820

RefSeq mRNA: 2 — MANE Select: NM_017740 NM_001145548, NM_017740

CCDS: CCDS10950, CCDS45538

Canonical transcript exons

ENST00000313732 — 8 exons

Exon	Start	End
ENSE00001352174	84995922	84996007
ENSE00001352184	85011286	85011535
ENSE00001376105	84990304	84990635
ENSE00001632655	84981870	84981994
ENSE00001933627	84974175	84976519
ENSE00003586594	84977924	84978005
ENSE00003609746	84979189	84979285
ENSE00003649199	84977095	84977225

Expression profiles

Bgee: expression breadth ubiquitous, 286 present calls, max score 99.13.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 51.7430 / max 291.9827, expressed in 1823 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
158376	41.6046	1821
158377	10.1384	1794

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	99.13	gold quality
monocyte	CL:0000576	97.75	gold quality
mononuclear cell	CL:0000842	97.74	gold quality
leukocyte	CL:0000738	97.63	gold quality
pylorus	UBERON:0001166	96.97	gold quality
granulocyte	CL:0000094	96.67	gold quality
cardia of stomach	UBERON:0001162	96.64	gold quality
oocyte	CL:0000023	95.99	gold quality
ileal mucosa	UBERON:0000331	95.94	gold quality
stromal cell of endometrium	CL:0002255	95.85	gold quality
decidua	UBERON:0002450	95.75	gold quality
calcaneal tendon	UBERON:0003701	95.67	gold quality
trachea	UBERON:0003126	95.53	gold quality
synovial joint	UBERON:0002217	95.42	gold quality
body of tongue	UBERON:0011876	95.32	gold quality
renal medulla	UBERON:0000362	95.25	gold quality
tongue	UBERON:0001723	94.85	gold quality
dorsal root ganglion	UBERON:0000044	94.82	gold quality
tibialis anterior	UBERON:0001385	94.80	silver quality
blood	UBERON:0000178	94.76	gold quality
trigeminal ganglion	UBERON:0001675	94.74	gold quality
layer of synovial tissue	UBERON:0007616	94.74	gold quality
transverse colon	UBERON:0001157	94.58	gold quality
urethra	UBERON:0000057	94.48	gold quality
pharyngeal mucosa	UBERON:0000355	94.45	gold quality
body of stomach	UBERON:0001161	94.43	gold quality
saphenous vein	UBERON:0007318	94.41	gold quality
superior surface of tongue	UBERON:0007371	94.40	gold quality
endocervix	UBERON:0000458	94.33	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	94.30	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.60

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

73 targeting ZDHHC7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-4679	99.76	69.19	1229
HSA-MIR-148A-3P	99.74	73.77	1700
HSA-MIR-148B-3P	99.74	73.75	1700
HSA-MIR-152-3P	99.74	73.75	1703
HSA-MIR-6745	99.74	65.33	1321
HSA-MIR-1208	99.70	68.28	1533
HSA-MIR-377-5P	99.70	65.28	712
HSA-MIR-6086	99.70	65.38	699

Literature-anchored findings (GeneRIF, showing 6)

• the DHHC-7 and -21 proteins are novel targets to selectively inhibit membrane sex steroid receptor localization and function (PMID:22031296)
• DHHC7-mediated palmitoylation of Fas allows a proper Fas expression level by preventing its degradation through the lysosomes. (PMID:25301068)
• The ZDHHC7-mediated SCRIB palmitoylation is critical for SCRIB membrane targeting, cell polarity and tumor suppression, providing new mechanistic insights of how dynamic protein palmitoylation regulates cell polarity and tumorigenesis. (PMID:27380321)
• identified DHHC7 as a JAM-C palmitoylating enzyme (PMID:28196865)
• demonstrated the importance of Zdhhc7 for assembling proper brain structure, function, and behavior on a system level in mice in a sex-related manner (PMID:31183559)
• Palmitoyl acyltransferase ZDHHC7 inhibits androgen receptor and suppresses prostate cancer. (PMID:37198397)

Cross-species orthologs

12 orthologs

Organism	Symbol	Gene ID
danio_rerio	zdhhc7	ENSDARG00000019484
mus_musculus	Zdhhc7	ENSMUSG00000031823
rattus_norvegicus	Zdhhc7	ENSRNOG00000017342
drosophila_melanogaster	Dnz1	FBGN0027453
drosophila_melanogaster	CG1407	FBGN0033474
drosophila_melanogaster	CG17287	FBGN0034202
caenorhabditis_elegans	dhhc-7	WBGENE00007637
caenorhabditis_elegans	dhhc-12	WBGENE00010323
caenorhabditis_elegans	dhhc-2	WBGENE00012948
caenorhabditis_elegans		WBGENE00014075
caenorhabditis_elegans		WBGENE00016620
caenorhabditis_elegans		WBGENE00020066

Paralogs (17): ZDHHC6 (ENSG00000023041), ZDHHC15 (ENSG00000102383), ZDHHC2 (ENSG00000104219), ZDHHC4 (ENSG00000136247), ZDHHC1 (ENSG00000159714), ZDHHC12 (ENSG00000160446), ZDHHC3 (ENSG00000163812), ZDHHC19 (ENSG00000163958), ZDHHC14 (ENSG00000175048), ZDHHC21 (ENSG00000175893), ZDHHC22 (ENSG00000177108), ZDHHC20 (ENSG00000180776), ZDHHC23 (ENSG00000184307), ZDHHC9 (ENSG00000188706), ZDHHC11 (ENSG00000188818), ZDHHC18 (ENSG00000204160), ZDHHC11B (ENSG00000206077)

Protein

Protein identifiers

Palmitoyltransferase ZDHHC7 — Q9NXF8 (reviewed: Q9NXF8)

Alternative names: Acyltransferase ZDHHC7, Zinc finger DHHC domain-containing protein 7

All UniProt accessions (3): Q9NXF8, H3BMI0, H3BNQ9

UniProt curated annotations — full annotation on UniProt →

Function. Golgi-localized palmitoyltransferase that catalyzes the addition of palmitate onto various protein substrates and therefore functions in several unrelated biological processes. Has no stringent fatty acid selectivity and in addition to palmitate can also transfer onto target proteins myristate from tetradecanoyl-CoA and stearate from octadecanoyl-CoA. Palmitoylates sex steroid hormone receptors, including ESR1, PGR and AR, thereby regulating their targeting to the plasma membrane and their function in rapid intracellular signaling upon binding of sex hormones. Palmitoylates GNAQ, a heterotrimeric G protein, regulating its dynamic localization at the plasma membrane and is thereby involved in GNAQ-dependent G protein-coupled receptor signaling pathways. Also functions in ligand-induced cell death by regulating the FAS signaling pathway through the palmitoylation and stabilization of the receptor at the plasma membrane. In epithelial cells, palmitoylates SCRIB and regulates its localization to the plasma membrane, regulating indirectly cell polarity and differentiation. Also palmitoylates JAM3 and promotes its expression at tight junctions and regulates its function in cell migration. Palmitoylates the glucose transporter GLUT4/SLC2A4 and controls the insulin-dependent translocation of GLUT4 to the plasma membrane. In brain, could also palmitoylate SNAP25 and DLG4/PSD95. Could also palmitoylate DNAJC5 and regulate its localization to the Golgi membrane. Could also palmitoylate NCDN. May play a role in follicle stimulation hormone (FSH) activation of testicular Sertoli cells. Activates pyroptosis by catalyzing palmitoylation of gasdermin-D (GSDMD).

Subunit / interactions. Homooligomers. Heterooligomers with ZDHHC3.

Subcellular location. Golgi apparatus membrane.

Post-translational modifications. Autopalmitoylated.

Domain organisation. The DHHC domain is required for palmitoyltransferase activity.

Similarity. Belongs to the DHHC palmitoyltransferase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9NXF8-1	1	yes
Q9NXF8-2	2

RefSeq proteins (2): NP_001139020, NP_060210* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001594	Palmitoyltrfase_DHHC	Domain
IPR039859	PFA4/ZDH16/20/ERF2-like	Family

Pfam: PF01529

Catalyzed reactions (Rhea), 3 shown:

• L-cysteinyl-[protein] + hexadecanoyl-CoA = S-hexadecanoyl-L-cysteinyl-[protein] + CoA (RHEA:36683)
• L-cysteinyl-[protein] + tetradecanoyl-CoA = S-tetradecanoyl-L-cysteinyl-[protein] + CoA (RHEA:59736)
• L-cysteinyl-[protein] + octadecanoyl-CoA = S-octadecanoyl-L-cysteinyl-[protein] + CoA (RHEA:59740)

UniProt features (16 total): topological domain 5, transmembrane region 4, sequence variant 2, chain 1, domain 1, active site 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NXF8-F1	83.85	0.65

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 160 (s-palmitoyl cysteine intermediate)

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9009391	Extra-nuclear estrogen signaling

MSigDB gene sets: 233 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_DN, GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_CARBOHYDRATE_TRANSPORT, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_LIPOPROTEIN_METABOLIC_PROCESS, GOBP_PROTEIN_TARGETING, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_PEPTIDYL_CYSTEINE_MODIFICATION, GOBP_PROTEIN_LOCALIZATION_TO_CELL_PERIPHERY, GOBP_POSITIVE_REGULATION_OF_TRANSMEMBRANE_TRANSPORT, GOBP_CELLULAR_RESPONSE_TO_INSULIN_STIMULUS, GOBP_HORMONE_MEDIATED_SIGNALING_PATHWAY, GOBP_PROTEIN_TARGETING_TO_MEMBRANE

GO Biological Process (17): protein targeting to membrane (GO:0006612), regulation of G protein-coupled receptor signaling pathway (GO:0008277), negative regulation of catabolic process (GO:0009895), positive regulation of D-glucose transmembrane transport (GO:0010828), peptidyl-L-cysteine S-palmitoylation (GO:0018230), protein palmitoylation (GO:0018345), androgen receptor signaling pathway (GO:0030521), polarized epithelial cell differentiation (GO:0030859), steroid hormone receptor signaling pathway (GO:0043401), glucose import in response to insulin stimulus (GO:0044381), progesterone receptor signaling pathway (GO:0050847), protein localization to plasma membrane (GO:0072659), regulation of protein localization to cell-cell junction (GO:0150106), regulation of Fas signaling pathway (GO:1902044), regulation of protein localization to plasma membrane (GO:1903076), positive regulation of epithelial to mesenchymal transition (GO:0010718), D-glucose transmembrane transport (GO:1904659)

GO Molecular Function (7): palmitoyltransferase activity (GO:0016409), protein-cysteine S-myristoyltransferase activity (GO:0019705), protein-cysteine S-palmitoyltransferase activity (GO:0019706), protein-cysteine S-stearoyltransferase activity (GO:0140439), protein binding (GO:0005515), transferase activity (GO:0016740), acyltransferase activity (GO:0016746)

GO Cellular Component (5): Golgi membrane (GO:0000139), nucleoplasm (GO:0005654), endoplasmic reticulum (GO:0005783), Golgi apparatus (GO:0005794), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
ESR-mediated signaling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein-cysteine S-acyltransferase activity	3
regulation of signal transduction	2
nuclear receptor-mediated steroid hormone signaling pathway	2
cellular anatomical structure	2
cytoplasm	2
endomembrane system	2
intracellular membrane-bounded organelle	2
protein targeting	1
establishment of protein localization to membrane	1
G protein-coupled receptor signaling pathway	1
catabolic process	1
negative regulation of metabolic process	1
regulation of catabolic process	1
regulation of D-glucose transmembrane transport	1
positive regulation of transmembrane transport	1
D-glucose transmembrane transport	1
peptidyl-S-diacylglycerol-L-cysteine biosynthetic process from peptidyl-cysteine	1
protein palmitoylation	1
protein lipidation	1
protein acylation	1
morphogenesis of a polarized epithelium	1
epithelial cell differentiation	1
hormone-mediated signaling pathway	1
cellular response to steroid hormone stimulus	1
cellular response to insulin stimulus	1
D-glucose import across plasma membrane	1
protein localization to membrane	1
protein localization to cell periphery	1
regulation of protein localization	1
protein localization to cell-cell junction	1
Fas signaling pathway	1
protein localization to plasma membrane	1
regulation of protein localization to cell periphery	1
regulation of protein localization to membrane	1
epithelial to mesenchymal transition	1
regulation of epithelial to mesenchymal transition	1
positive regulation of cell differentiation	1
positive regulation of multicellular organismal process	1
hexose transmembrane transport	1
acyltransferase activity, transferring groups other than amino-acyl groups	1

Protein interactions and networks

STRING

712 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZDHHC7	LYPLA2	O95372	597
ZDHHC7	ABHD17A	Q96GS6	515
ZDHHC7	PPT1	P50897	506
ZDHHC7	PPT2	Q9UMR5	485
ZDHHC7	ZDHHC8	Q9ULC8	483
ZDHHC7	ZDHHC17	Q8IUH5	451
ZDHHC7	ZDHHC13	Q8IUH4	446
ZDHHC7	ABHD17B	Q5VST6	434
ZDHHC7	SDR42E1	Q8WUS8	425
ZDHHC7	LYPLA1	O75608	423
ZDHHC7	ZDHHC3	Q9NYG2	422
ZDHHC7	GOLGA7	Q7Z5G4	420
ZDHHC7	ABHD17C	Q6PCB6	417
ZDHHC7	ZDHHC14	Q8IZN3	413
ZDHHC7	ZDHHC5	Q9C0B5	407

IntAct

38 interactions, top by confidence:

A	B	Type	Score
	ZDHHC7	psi-mi:“MI:0915”(physical association)	0.370
CCL1	ZDHHC7	psi-mi:“MI:0915”(physical association)	0.370
CCL2	ZDHHC7	psi-mi:“MI:0915”(physical association)	0.370
CCL22	ZDHHC7	psi-mi:“MI:0915”(physical association)	0.370
CCL3L1	ZDHHC7	psi-mi:“MI:0915”(physical association)	0.370
CCL8	ZDHHC7	psi-mi:“MI:0915”(physical association)	0.370
IFNL1	ZDHHC7	psi-mi:“MI:0915”(physical association)	0.370
IFNL4	ZDHHC7	psi-mi:“MI:0915”(physical association)	0.370
IL17A	ZDHHC7	psi-mi:“MI:0915”(physical association)	0.370
IL18	ZDHHC7	psi-mi:“MI:0915”(physical association)	0.370
IL31	ZDHHC7	psi-mi:“MI:0915”(physical association)	0.370
LTA	ZDHHC7	psi-mi:“MI:0915”(physical association)	0.370
PF4V1	ZDHHC7	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (32): ZDHHC7 (Affinity Capture-RNA), ZDHHC7 (Affinity Capture-RNA), CKM (Affinity Capture-MS), TMEM259 (Affinity Capture-MS), REEP5 (Affinity Capture-MS), NDFIP1 (Affinity Capture-MS), TMEM186 (Affinity Capture-MS), MARCH6 (Affinity Capture-MS), CKM (Affinity Capture-MS), MARCH6 (Affinity Capture-MS), TMEM186 (Affinity Capture-MS), NDFIP1 (Affinity Capture-MS), ZDHHC7 (Affinity Capture-RNA), ZDHHC7 (Two-hybrid), ZDHHC7 (Two-hybrid)

ESM2 similar proteins: A0A087WTH1, A0A125YWU9, A0PK84, A6PVL3, C9JQL5, F1QHM7, F1QX91, O15503, O41933, O70418, O88728, P0DI73, P13164, P26376, Q01628, Q01629, Q08755, Q0II74, Q21642, Q32L65, Q3UNB8, Q3YBM2, Q5FVR1, Q5FWL7, Q5I0I2, Q5R8D6, Q5RF75, Q5Y5T3, Q6DHI1, Q76IC6, Q7M734, Q7TQJ1, Q8BGI3, Q8CES1, Q8CFA6, Q8IYP9, Q8N6L7, Q8WVZ1, Q91WU6, Q921C1

Diamond homologs: A0A0R4IDP3, A2CEX1, A2VEY9, A5WVX9, B3DN87, C8VCL4, E1BLT8, E7F021, E7F587, E7FBS9, E7FH11, E9PTT0, E9QCD3, F1Q7H8, F1QAM1, F1QHM7, F1QX91, F1QXD3, F1R013, F1RE57, J9VJ99, O60069, O74384, O80685, P42836, P59267, P59268, Q04629, Q0VC89, Q10L01, Q2TGJ1, Q2TGJ4, Q2TGK3, Q2THW7, Q2THW8, Q2THW9, Q2THX0, Q2THX1, Q4R690, Q4WZL8

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 21 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
chemokine-mediated signaling pathway	5	85.3×	2e-07
antimicrobial humoral immune response mediated by antimicrobial peptide	6	51.2×	2e-07
positive regulation of cell migration	6	19.5×	1e-05
cell-cell signaling	5	18.3×	2e-04
inflammatory response	8	15.9×	6e-07

Disease & clinical

Clinical variants and AI predictions

ClinVar

47 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	39
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1932 predictions. Top by Δscore:

Variant	Effect	Δscore
16:84977089:GCTT:G	donor_loss	1.0000
16:84977090:CTTAC:C	donor_loss	1.0000
16:84977091:TTACC:T	donor_loss	1.0000
16:84977094:C:CT	donor_loss	1.0000
16:84978003:CAT:C	acceptor_gain	1.0000
16:84979183:ACTT:A	donor_loss	1.0000
16:84979184:CTT:C	donor_loss	1.0000
16:84979185:TT:T	donor_loss	1.0000
16:84979187:A:AC	donor_gain	1.0000
16:84979187:A:T	donor_loss	1.0000
16:84979188:C:CA	donor_gain	1.0000
16:84979188:CA:C	donor_gain	1.0000
16:84979188:CAG:C	donor_gain	1.0000
16:84979188:CAGT:C	donor_gain	1.0000
16:84979188:CAGTG:C	donor_gain	1.0000
16:84979281:AAATA:A	acceptor_gain	1.0000
16:84979282:AATA:A	acceptor_gain	1.0000
16:84979283:ATA:A	acceptor_gain	1.0000
16:84979283:ATAC:A	acceptor_loss	1.0000
16:84979284:TA:T	acceptor_gain	1.0000
16:84979285:AC:A	acceptor_loss	1.0000
16:84979286:C:CC	acceptor_gain	1.0000
16:84979286:CTGAA:C	acceptor_loss	1.0000
16:84981867:TACCT:T	donor_loss	1.0000
16:84981868:AC:A	donor_loss	1.0000
16:84981869:C:CT	donor_loss	1.0000
16:84981991:CCCC:C	acceptor_gain	1.0000
16:84981992:CCCC:C	acceptor_gain	1.0000
16:84981993:CC:C	acceptor_gain	1.0000
16:84981993:CCCT:C	acceptor_loss	1.0000

AlphaMissense

2020 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:84979201:A:C	F175L	1.000
16:84979201:A:T	F175L	1.000
16:84979203:A:G	F175L	1.000
16:84979223:C:A	G168V	1.000
16:84979223:C:T	G168E	1.000
16:84979228:A:C	C166W	1.000
16:84979229:C:T	C166Y	1.000
16:84979230:A:G	C166R	1.000
16:84979231:A:C	N165K	1.000
16:84979231:A:T	N165K	1.000
16:84979234:G:C	N164K	1.000
16:84979234:G:T	N164K	1.000
16:84979242:A:G	W162R	1.000
16:84979242:A:T	W162R	1.000
16:84979246:G:C	C160W	1.000
16:84979247:C:G	C160S	1.000
16:84979247:C:T	C160Y	1.000
16:84979248:A:G	C160R	1.000
16:84979248:A:T	C160S	1.000
16:84979249:G:C	H159Q	1.000
16:84979249:G:T	H159Q	1.000
16:84979251:G:C	H159D	1.000
16:84979251:G:T	H159N	1.000
16:84979252:A:C	H158Q	1.000
16:84979252:A:T	H158Q	1.000
16:84979253:T:A	H158L	1.000
16:84979254:G:C	H158D	1.000
16:84979254:G:T	H158N	1.000
16:84979255:A:C	D157E	1.000
16:84979255:A:T	D157E	1.000

dbSNP variants (sampled 300 via entrez): RS1000044375 (16:85011854 G>A), RS1000132206 (16:84998927 G>A,C), RS1000239549 (16:84995085 C>A,G), RS1000243452 (16:85015588 C>T), RS1000393313 (16:85019884 C>G,T), RS1000418835 (16:85000171 C>T), RS1000467133 (16:84990737 G>A,C,T), RS1000468272 (16:85019497 C>A,T), RS1000472241 (16:85027522 C>T), RS1000550247 (16:85004207 C>T), RS1000561113 (16:85024261 T>C), RS1000566693 (16:84996631 A>C,G), RS1000662508 (16:85000230 G>A,C), RS1000663401 (16:85028713 C>G,T), RS1000732809 (16:85000047 G>A)

Disease associations

OMIM: gene MIM:614604 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST000175_24	Height	8.000000e-07
GCST002647_117	Height	5.000000e-10
GCST008507_2	Stress sensitivity (neuroticism score x major depressive disorder status interaction)	2.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007660	neuroticism measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066246 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs3210967	Efficacy	3	methylphenidate	Attention Deficit Disorder with Hyperactivity

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs3210967	ZDHHC7	3	0.00	1	methylphenidate

ChEMBL bioactivities

1 potent at pChembl≥5 of 2 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.36	IC50	4400	nM	CHEMBL5567020

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
S-(2-acetamidoethyl) 2-bromohexadecanethioate	2084115: Inhibition of ZDHHC7 (unknown origin)	ic50	4.4000	uM

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, increases methylation, affects cotreatment	3
Resveratrol	affects cotreatment, decreases expression, increases expression	2
Arsenic	affects methylation, decreases expression, increases abundance	2
Estradiol	decreases expression	2
aristolochic acid I	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
beta-lapachone	increases expression	1
sodium arsenite	increases abundance, decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
Temozolomide	decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Benzo(a)pyrene	affects methylation	1
Caffeine	decreases phosphorylation	1
Coumestrol	affects cotreatment, decreases expression	1
Hydralazine	affects cotreatment, increases expression	1
Ozone	affects expression, increases abundance	1
Plant Extracts	affects cotreatment, increases expression	1
Smoke	increases expression	1
Thiram	decreases expression	1
Tretinoin	increases expression	1
Urethane	increases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Aflatoxin B1	decreases methylation	1
Cadmium Chloride	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5524588	Binding	Inhibition of ZDHHC7 (unknown origin)	Modulators for palmitoylation of proteins and small molecules. — Eur J Med Chem

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2LQ	Abcam HeLa ZDHHC7 KO	Cancer cell line	Female
CVCL_TZ04	HAP1 ZDHHC7 (-) 1	Cancer cell line	Male
CVCL_TZ05	HAP1 ZDHHC7 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.